Verona Pharma plc Verona Pharma To Present At H.C. Wainwright 22nd Annual Global Virtual Investment Conference

 
TIDMVRP 
 
   LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona 
Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases, announces 
that David Zaccardelli, Chief Executive Officer and President, will 
present a company overview at the H.C. Wainwright 22(nd) Annual Global 
Virtual Investment Conference on Monday, September 14, 2020 at 5:00 PM 
ET. 
 
   A live webcast of the event will be available on the Events and 
Presentations link on the Investors page of the Company's website, 
https://www.globenewswire.com/Tracker?data=kNmzIhE0stHcg7SXr-qyUZrvEvLnceJvQlqo6uTYOr_VeNhtHtMRqrPJM-OQixCKp4dqdrA3rdiXqShy-mo3aRc1SIgx-rqRT4IC_jivMcs= 
www.veronapharma.com, and an audio replay will be available there for 30 
days. 
 
 
 
 
 
  Verona Pharma plc                                       Tel: +44 (0)20 3283 4200 
------------------------------------------------------  --------------------------- 
  Victoria Stewart, Director of Communications            info@veronapharma.com 
------------------------------------------------------  --------------------------- 
 
  N+1 Singer                                              Tel: +44 (0)20 7496 3000 
   (Nominated Adviser and UK Broker) 
------------------------------------------------------  --------------------------- 
  Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
   Finance) 
------------------------------------------------------  --------------------------- 
  Tom Salvesen (Corporate Broking) 
------------------------------------------------------  --------------------------- 
 
  Optimum Strategic Communications                        Tel: +44 (0)20 950 9144 
   (European Media and Investor Enquiries)                 verona@optimumcomms.com 
------------------------------------------------------  --------------------------- 
  Mary Clark / Eva Haas / Shabnam Bashir 
------------------------------------------------------  --------------------------- 
 
  Argot Partners                                          Tel: +1 212-600-1902 
   (US Investor Enquiries)                                 verona@argotpartners.com 
------------------------------------------------------  --------------------------- 
  Kimberly Minarovich / Michael Barron 
------------------------------------------------------  --------------------------- 
 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. The Company plans to 
initiate its Phase 3 clinical program ENHANCE ("Ensifentrine as a Novel 
inHAled Nebulized COPD thErapy") later in 2020 for nebulized 
ensifentrine for COPD maintenance treatment. The Company raised gross 
proceeds of $200 million through a private placement in July 2020 and 
expects the funds to support its operations and Phase 3 clinical program 
into 2023. Two additional formulations of ensifentrine are currently in 
Phase 2 development for the treatment of COPD: dry powder inhaler 
("DPI") and pressurized metered-dose inhaler ("pMDI"). Ensifentrine also 
has potential applications in COVID-19, cystic fibrosis, asthma and 
other respiratory diseases. For more information, please visit 
https://www.globenewswire.com/Tracker?data=kNmzIhE0stHcg7SXr-qyUZj7gOU2Jw8y7EEspnq7YrC0Qv1O3lB97DI7xJNLwxCjL3FdJ0A8a4o2PdNMFdDE7l6Jge54OBarmH-Y34d16Qk= 
www.veronapharma.com. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, the development of ensifentrine, the 
progress and timing of initiation of clinical trials, the goals and 
design of clinical trials, the potential for ensifentrine to be a 
first-in-class phosphodiesterase 3 and 4 inhibitor and to be the first 
therapy for the treatment of respiratory diseases to combine 
bronchodilator and anti-inflammatory effects in one compound, the 
sufficiency of funds to support its operations and Phase 3 clinical 
program into 2023, and the potential of ensifentrine in the treatment of 
COPD, COVID-19, cystic fibrosis, asthma and other respiratory diseases. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of ensifentrine, 
which may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of ensifentrine, our only product candidate 
under development; economic, political, regulatory and other risks 
involved with international operations; the lengthy and expensive 
process of clinical drug development, which has an uncertain outcome; 
serious adverse, undesirable or unacceptable side effects associated 
with ensifentrine, which could adversely affect our ability to develop 
or commercialize ensifentrine; potential delays in enrolling patients, 
which could adversely affect our research and development efforts and 
the completion of our clinical trials; we may not be successful in 
developing ensifentrine for multiple indications; our ability to obtain 
approval for and commercialize ensifentrine in multiple major 
pharmaceutical markets; misconduct or other improper activities by our 
employees, consultants, principal investigators, and third-party service 
providers; our future growth and ability to compete depends on retaining 
our key personnel and recruiting additional qualified personnel; 
material differences between our "top-line" data and final data; our 
reliance on third parties, including clinical research organizations, 
clinical investigators, manufacturers and suppliers, and the risks 
related to these parties' ability to successfully develop and 
commercialize ensifentrine; and lawsuits related to patents covering 
ensifentrine and the potential for our patents to be found invalid or 
unenforceable; and our vulnerability to natural disasters, global 
economic factors and other unexpected events, including health epidemics 
or pandemics like the novel coronavirus (COVID-19). These and other 
important factors under the caption "Risk Factors" in our Annual Report 
on Form 20-F filed with the Securities and Exchange Commission ("SEC") 
on February 27, 2020, under the caption "Risk Factors" in our 
Registration Statement on Form F-1 filed with the SEC on August 17, 
2020, and our other reports filed with the SEC, could cause actual 
results to differ materially from those indicated by the forward-looking 
statements made in this press release. Any such forward-looking 
statements represent management's estimates as of the date of this press 
release. While we may elect to update such forward-looking statements at 
some point in the future, we disclaim any obligation to do so, even if 
subsequent events cause our views to change. These forward-looking 
statements should not be relied upon as representing our views as of any 
date subsequent to the date of this press release.
(END) Dow Jones Newswires
September 02, 2020 02:00 ET (06:00 GMT)
Verona Pharma (LSE:VRP)
過去株価チャート
から 12 2024 まで 1 2025